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International comparisons of indicators of healthcare perfor-
mance, quality and safety provide an important opportunity to
explore reasons for their variations in order to find ways to
improve both the indicators and the quality of care. We aimed
to compare rates of hospital adverse events internationally and
to investigate possible clinical and health system determinants
of their variations.
Methods
We used hospital discharge diagnoses to measure rates
of symptomatic venous thromboembolic events (VTE)
in patients hospitalized for hip arthroplasty in Canada,
France, New-Zealand, Switzerland and the USA. We used
these coded diagnoses to measure VTE rates using an
existing algorithm (AHRQ Patient Safety Indicator 12).
We examined associations between VTE and gender, age,
length of stay (LOS), number of discharge diagnoses recorded
(Ndiag), and performance of ultrasonography before discharge
(US).
Results
VTE rates were 0.84% in Canada, 1.41% in France, 0.84% in
New-Zealand, 0.37% in Switzerland, 0.66% in the USA. Age,
gender, LOS, Ndiag and US could have influenced VTE rates.
For instance, France, where the highest VTE rate was observed,
was also the only country with routine reported use of US
before discharge (>17% vs <1% in other countries), which was
even more frequent in private hospitals. The mean value of
Ndiag was close to 7 in the USA, and varied between 2 and 3 in
the other countries.
Conclusions
VTE rates varied across countries. These differences could be
linked to differences in coding practices, as well as differences
in clinical and health systems determinants (e.g., higher
systematic US assessment in France and probable increased
number of asymptomatic VTE coded). The interpretation of
differences in international comparisons of healthcare asso-
ciated VTE rates should be cautious; possible determinants of
these differences should be considered.
Key messages
 Understanding and reducing heterogeneity in international
comparisons of adverse events of healthcare is crucial
 Caution is needed when interpreting international compar-
isons of adverse events of healthcare
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